Curis Company Profile (NASDAQ:CRIS)

About Curis

Curis logoCuris, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CRIS
  • CUSIP: 23126910
Key Metrics:
  • Previous Close: $2.37
  • 50 Day Moving Average: $2.77
  • 200 Day Moving Average: $2.66
  • 52-Week Range: $140,549,000.00 - $1.34
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.77
  • P/E Growth: 0.00
  • Market Cap: $333.10M
  • Outstanding Shares: 140,549,000
  • Beta: 1.89
Profitability:
  • Net Margins: -861.64%
  • Return on Equity: -99.45%
  • Return on Assets: -63.44%
Debt:
  • Debt-to-Equity Ratio: 0.42%
  • Current Ratio: 4.54%
  • Quick Ratio: 4.54%
Additional Links:
Companies Related to Curis:

Analyst Ratings

Consensus Ratings for Curis (NASDAQ:CRIS) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.50 (132.07% upside)

Analysts' Ratings History for Curis (NASDAQ:CRIS)
Show:
DateFirmActionRatingPrice TargetDetails
10/12/2016RBC Capital MarketsSet Price TargetBuy$7.00View Rating Details
9/8/2016FBR & CoReiterated RatingBuyView Rating Details
9/7/2016Robert W. BairdReiterated RatingOutperform$7.00View Rating Details
5/5/2016Cowen and CompanyInitiated CoverageOutperformView Rating Details
3/1/2016SunTrust Banks, Inc.Initiated CoverageBuy$3.00View Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$5.00View Rating Details
7/6/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperformView Rating Details
5/16/2015Stifel NicolausReiterated RatingHoldView Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Curis (NASDAQ:CRIS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017($0.10)N/AView Earnings Details
11/3/2016Q316($0.10)($0.21)$1.84 million$1.80 millionViewListenView Earnings Details
8/4/2016Q216($0.09)($0.09)$2.05 million$1.70 millionViewListenView Earnings Details
5/9/2016Q116($0.08)($0.07)$2.30 million$1.70 millionViewListenView Earnings Details
2/29/2016Q415($0.12)($0.10)$2.98 million$2.10 millionViewListenView Earnings Details
11/9/2015Q315($0.08)($0.04)$2.82 million$2.00 millionViewN/AView Earnings Details
8/6/2015Q215($0.06)($0.06)$3.50 million$2.10 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$2.27 million$1.17 millionViewN/AView Earnings Details
2/24/2015Q4 14($0.07)($0.07)$2.69 million$2.00 millionViewN/AView Earnings Details
11/10/2014Q314($0.04)($0.06)$4.13 million$1.80 millionViewN/AView Earnings Details
8/7/2014Q214($0.05)($0.02)$3.46 million$4.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.06)($0.06)$1.88 million$1.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.08)($0.05)$1.59 million$1.52 millionViewN/AView Earnings Details
11/5/2013Q313($0.01)($0.02)$6.44 million$7.20 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.05)($0.02)$4.43 million$5.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.05)($0.06)$3.86 million$0.90 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.08)($0.15)$2.07 million$1.69 millionViewN/AView Earnings Details
11/6/2012Q312($0.08)($0.04)$1.01 million$0.60 millionViewN/AView Earnings Details
8/2/2012($0.05)($0.04)ViewN/AView Earnings Details
5/8/2012$0.02$0.03ViewN/AView Earnings Details
10/27/2011($0.07)($0.05)ViewN/AView Earnings Details
7/28/2011($0.07)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Curis (NASDAQ:CRIS)
Current Year EPS Consensus Estimate: $-0.43 EPS
Next Year EPS Consensus Estimate: $-0.35 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.08)($0.05)($0.07)
Q2 20164($0.10)($0.05)($0.08)
Q3 20164($0.11)($0.07)($0.09)
Q4 20164($0.12)($0.07)($0.09)
Q1 20171($0.08)($0.08)($0.08)
Q2 20171($0.07)($0.07)($0.07)
Q3 20171($0.07)($0.07)($0.07)
Q4 20171($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Curis (NASDAQ:CRIS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Curis (NASDAQ:CRIS)
Insider Ownership Percentage: 6.09%
Institutional Ownership Percentage: 49.49%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/7/2016Discovery Technologie AurigeneMajor ShareholderBuy10,208,333$2.40$24,499,999.20View SEC Filing  
5/27/2016Martyn D GreenacreDirectorSell15,000$1.69$25,350.00View SEC Filing  
5/26/2016Kenneth I KaitinDirectorSell15,000$1.76$26,400.00View SEC Filing  
12/30/2015Daniel R. PasseriDirectorSell14,400$3.01$43,344.00View SEC Filing  
12/29/2015Daniel R. PasseriDirectorSell11,200$2.91$32,592.00View SEC Filing  
12/28/2015Daniel R. PasseriDirectorSell13,600$2.85$38,760.00View SEC Filing  
12/23/2015Daniel R. PasseriDirectorSell48,900$2.78$135,942.00View SEC Filing  
12/21/2015Daniel R. PasseriDirectorSell289,000$2.99$864,110.00View SEC Filing  
8/27/2014Ali Ph.D. FattaeyCEOBuy62,890$1.60$100,624.00View SEC Filing  
12/11/2013Ali Ph.D. FattaeyCOOBuy3,000$2.52$7,560.00View SEC Filing  
11/12/2013Michael GrayCFOBuy10,000$2.86$28,600.00View SEC Filing  
11/8/2013Kenneth PientaDirectorBuy20,000$2.95$59,000.00View SEC Filing  
8/16/2013James McnabDirectorSell50,000$4.00$200,000.00View SEC Filing  
12/6/2012Daniel R PasseriCEOBuy25,000$3.03$75,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Curis (NASDAQ:CRIS)
DateHeadline
News IconShares in View: Curis Inc (CRIS) - The Standard (NASDAQ:CRIS)
6milestandard.com - February 24 at 9:53 PM
News IconAnalysts Peer Into Their Crystal Balls For Curis, Inc. (NASDAQ:CRIS): Where Is It headed? - Winfield Review (NASDAQ:CRIS)
winfieldreview.com - February 24 at 12:14 PM
News IconEquity Rundown: Checking the Levels for Curis, Inc. (NASDAQ:CRIS) - BVN (NASDAQ:CRIS)
bvnewsjournal.com - February 24 at 12:14 PM
News IconCompany Spotlight on Shares of Curis, Inc. (NASDAQ:CRIS) - Sherwood Daily (NASDAQ:CRIS)
sherwooddaily.com - February 23 at 9:27 PM
News IconThe Curis, Inc. (CRIS) Receives $5.50 Consensus PT from Analysts - Petro Global News 24 (NASDAQ:CRIS)
petroglobalnews24.com - February 23 at 9:27 PM
News IconCuris Inc CRIS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CRIS)
www.bioportfolio.com - February 22 at 10:23 AM
News IconShould You Buy Or Sell Curis, Inc. (CRIS) On Analyst Concensus? - NewsDen (NASDAQ:CRIS)
newsden.net - February 21 at 4:41 PM
News IconWhat are Brokerage Firms Saying About Curis, Inc. (NASDAQ:CRIS)? - Aiken Advocate (NASDAQ:CRIS)
aikenadvocate.com - February 21 at 4:41 PM
finance.yahoo.com logoCuris to Present at the 2017 RBC Capital Markets Global Healthcare Conference (NASDAQ:CRIS)
finance.yahoo.com - February 17 at 5:42 PM
News IconStock Update on Earnings & Estimates for Curis, Inc. (NASDAQ:CRIS) - Aiken Advocate (NASDAQ:CRIS)
aikenadvocate.com - February 14 at 10:24 PM
News IconMarket Focus: Checking Up on Shares of Curis, Inc. (NASDAQ:CRIS ... - Benton Bulletin (NASDAQ:CRIS)
bentonbulletin.com - February 11 at 2:54 AM
News IconShare Levels in Review for Curis Inc. (CRIS) - Davidson Register (NASDAQ:CRIS)
davidsonregister.com - February 10 at 4:51 PM
News IconEquity Focus: Indicator Check on Shares of Curis Inc. (CRIS) - Rives Journal (NASDAQ:CRIS)
rivesjournal.com - February 7 at 10:37 PM
News IconVolatility Watch on Shares of Curis, Inc. (NASDAQ:CRIS) - Gilbert Daily (NASDAQ:CRIS)
gilbertdaily.com - January 30 at 8:36 AM
News IconInvestor Monitor: Narrowing in on Curis, Inc. (NASDAQ:CRIS) - The Tribune (NASDAQ:CRIS)
lakecitytribune.com - January 27 at 5:58 PM
News IconIndicator Level Summary for Curis Inc. (CRIS) - Sherwood Daily (NASDAQ:CRIS)
sherwooddaily.com - January 27 at 5:58 PM
News IconAre Discerning Investors Interested in These Shares: Curis, Inc. (NASDAQ:CRIS) - Prospect Journal (NASDAQ:CRIS)
prospectjournal.com - January 26 at 10:40 PM
News IconWilliams %R, RSI, and ADX Update for Curis Inc. (CRIS) - Sherwood Daily (NASDAQ:CRIS)
sherwooddaily.com - January 26 at 5:39 PM
News IconBargain Hunter's Delight: What's the Latest on Curis, Inc. (NASDAQ:CRIS) - Prospect Journal (NASDAQ:CRIS)
prospectjournal.com - January 25 at 5:37 PM
News IconReviewing Indicator Levels for Curis Inc. (CRIS) - Sherwood Daily (NASDAQ:CRIS)
sherwooddaily.com - January 25 at 3:08 AM
News IconStock Perspective: Curis, Inc. (NASDAQ:CRIS) Earnings in View - Aiken Advocate (NASDAQ:CRIS)
aikenadvocate.com - January 25 at 3:08 AM
News IconStock Cutting The Mustard Mid-Session: Curis, Inc. (NASDAQ:CRIS) - Aiken Advocate (NASDAQ:CRIS)
aikenadvocate.com - January 25 at 3:08 AM
News IconWhat The Charts Are Saying About Curis, Inc. (NASDAQ:CRIS) - The Tribune (NASDAQ:CRIS)
lakecitytribune.com - January 23 at 9:48 PM
News IconFocus on RSI and CCI Levels: Curis Inc. (CRIS) - Sherwood Daily (NASDAQ:CRIS)
sherwooddaily.com - January 20 at 5:42 PM
News IconMoving Averages in Focus on Shares of Curis Inc. (CRIS) - Sherwood Daily (NASDAQ:CRIS)
sherwooddaily.com - January 19 at 10:47 PM
News IconCan This Stock Price Climb The Ladder: Curis, Inc. (NASDAQ:CRIS ... - Prospect Journal (NASDAQ:CRIS)
prospectjournal.com - January 19 at 10:47 PM
News IconAmplified Volatility Spotted in Shares of Curis, Inc. (NASDAQ:CRIS) - Wall Street Beacon (NASDAQ:CRIS)
wsbeacon.com - January 19 at 10:47 PM
News IconCan This Stock Gain Any Traction: Curis, Inc. (NASDAQ:CRIS) - Prospect Journal (NASDAQ:CRIS)
prospectjournal.com - January 18 at 4:50 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Curis, Inc. (NASDAQ:CRIS) - Wall Street Beacon (NASDAQ:CRIS)
wsbeacon.com - January 17 at 10:24 PM
News IconAt the Focal Point, Checking in on Curis, Inc. (NASDAQ:CRIS) - Prospect Journal (NASDAQ:CRIS)
prospectjournal.com - January 17 at 10:24 PM
News IconStock Momentum Skidding to a Halt For Curis, Inc. (NASDAQ:CRIS) - Wall Street Beacon (NASDAQ:CRIS)
wsbeacon.com - January 17 at 10:24 PM
News IconWill The Needle Move For Curis, Inc. (NASDAQ:CRIS) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:CRIS)
wsbeacon.com - January 16 at 4:30 PM
News IconStock ABR Curis, Inc. (NASDAQ:CRIS) At 1 | Stock Observer - Stock Observer (NASDAQ:CRIS)
www.thestockobserver.com - January 13 at 10:15 PM
capitalcube.com logoCuris, Inc. – Value Analysis (NASDAQ:CRIS) : January 13, 2017 (NASDAQ:CRIS)
www.capitalcube.com - January 13 at 5:13 PM
4-traders.com logoAgios Pharmaceuticals : Technical Reports on Biotech Stocks -- Halozyme Therapeutics, Keryx Biopharma, Curis, and Agios Pharma (NASDAQ:CRIS)
www.4-traders.com - January 12 at 4:52 PM
News IconTechnical Reports on Biotech Stocks -- Halozyme Therapeutics, Keryx Biopharma, Curis, and Agios Pharma (NASDAQ:CRIS)
www.kait8.com - January 12 at 4:52 PM
capitalcube.com logoCuris, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : January 12, 2017 (NASDAQ:CRIS)
www.capitalcube.com - January 12 at 4:52 PM
News IconStock Getting Tripped Up In Session: Curis, Inc. (NASDAQ:CRIS) - Wall Street Beacon (NASDAQ:CRIS)
wsbeacon.com - January 11 at 9:58 PM
News IconStock Reaching Most Volatile List Today: Curis, Inc. (NASDAQ:CRIS) - Wall Street Beacon (NASDAQ:CRIS)
wsbeacon.com - January 11 at 9:58 PM
smarteranalyst.com logoStock Update (NASDAQ:CRIS): Curis, Inc. and Aurigene Extend Exclusivity Period Of Immuno-Oncology And Precision ... - Smarter Analyst (NASDAQ:CRIS)
www.smarteranalyst.com - January 10 at 5:20 PM
streetinsider.com logoCuris (CRIS) Exercises Option on Aurigene Collaboration (NASDAQ:CRIS)
www.streetinsider.com - January 9 at 5:38 PM
us.rd.yahoo.com logoCuris and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration (NASDAQ:CRIS)
us.rd.yahoo.com - January 9 at 5:38 PM
us.rd.yahoo.com logo7:09 am Curis exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option agreement established in January, 2015 (NASDAQ:CRIS)
us.rd.yahoo.com - January 9 at 5:38 PM
feeds.reuters.com logoBRIEF-Curis Inc exercised its option to extend exclusivity period with Aurigene (NASDAQ:CRIS)
feeds.reuters.com - January 9 at 7:28 AM
publicnow.com logoCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:CRIS)
www.publicnow.com - January 6 at 4:55 PM
investornewswire.com logoCuris, Inc. (NASDAQ:CRIS) Records An Impact Score Of 89 - Investor Newswire (NASDAQ:CRIS)
www.investornewswire.com - December 29 at 4:52 PM
News IconStock ABR Of Curis, Inc. (NASDAQ:CRIS) At 1 - Stock Observer (NASDAQ:CRIS)
www.thestockobserver.com - December 29 at 4:52 PM
capitalcube.com logoETFs with exposure to Curis, Inc. : December 27, 2016 (NASDAQ:CRIS)
www.capitalcube.com - December 27 at 4:44 PM
News IconTop Stock With Upside & Growth Potential: Curis, Inc. (NASDAQ:CRIS) - Prospect Journal (NASDAQ:CRIS)
prospectjournal.com - December 27 at 12:10 PM
News IconFinish Line Inc (FINL) is Downgraded by Citigroup to Neutral (NASDAQ:CRIS)
nflnewsdesk.com - December 21 at 10:18 PM

Social

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Where is Curis' stock going? Where will Curis' stock price be in 2017?

6 equities research analysts have issued 1 year target prices for Curis' shares. Their forecasts range from $3.00 to $7.00. On average, they anticipate Curis' share price to reach $5.50 in the next year.

When will Curis announce their earnings?

Curis is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns Curis stock?

Curis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (10.49%), State Street Corp (1.18%), Marshall Wace LLP (0.31%), Renaissance Technologies LLC (0.26%), Focused Wealth Management Inc (0.13%) and Metropolitan Life Insurance Co. NY (0.06%). Company insiders that own Curis stock include Daniel R Passeri, Discovery Technologie Aurigene, Kenneth I Kaitin and Martyn D Greenacre.

Who sold Curis stock? Who is selling Curis stock?

Curis' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP and Focused Wealth Management Inc. Company insiders that have sold Curis stock in the last year include Kenneth I Kaitin and Martyn D Greenacre.

Who bought Curis stock? Who is buying Curis stock?

Curis' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, State Street Corp, Two Sigma Investments LP, Fred Alger Management Inc., Oxford Asset Management, A.R.T. Advisors LLC, Dynamic Technology Lab Private Ltd and Metropolitan Life Insurance Co. NY.

How do I buy Curis stock?

Shares of Curis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Curis stock cost?

One share of Curis stock can currently be purchased for approximately $2.37.

Curis (NASDAQ:CRIS) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Curis (NASDAQ:CRIS)

Earnings History Chart

Earnings by Quarter for Curis (NASDAQ:CRIS)

Dividend History Chart

Dividend Payments by Quarter for Curis (NASDAQ:CRIS)

Last Updated on 2/26/2017 by MarketBeat.com Staff